Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRON TAVI
2023-505095-29-03Phase 4Authorised
- Sponsor
- Erasmus MC
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in aortic stenosis (AS) and iron deficiency anemia (IDA) comparing Ferinject arm with Placebo or standard care arm (2 arms). Primary endpoints: Quality of life at 6 months and Exercise capacity at 6 months. Planned start Dec 2023; status: authorised.
02
Drugs
ferric carboxymaltose
03
Conditions
aortic stenosis (AS)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2023-505095-29-03.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505095-29-03.